Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT06814600)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06814600 Sponsor: Centre Hospitalier Universitaire Saint Pierre Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06814600 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Inflammatory Bowel Disease (IBD), confirmed through clinical assessment, a camera examination of the bowel, and tissue analysis, following current international IBD guidelines.
People who are willing to give their consent to take part in the study.

Who may not be able to join:

People who already have a known liver condition, such as autoimmune hepatitis, primary biliary cholangitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, or who have tested positive for hepatitis B or C.
People who have a history of liver cancer or have previously had a liver transplant.
People with a history of heavy alcohol use, defined as more than 3 standard drinks per day for women or more than 5 standard drinks per day for men.
People who are pregnant at the time of joining the study.
People for whom a liver stiffness scan (called elastography) could not be completed or where that scan data is missing.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +3225353296

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06814600

Sponsor: Centre Hospitalier Universitaire Saint Pierre

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: +3225353296

More information: https://clinicaltrials.gov/study/NCT06814600

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Inflammatory Bowel Disease (IBD), confirmed through clinical assessment, a camera examination of the bowel, and tissue analysis, following current international IBD guidelines.
People who are willing to give their consent to take part in the study.

Who may not be able to join:

People who already have a known liver condition, such as autoimmune hepatitis, primary biliary cholangitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, or who have tested positive for hepatitis B or C.
People who have a history of liver cancer or have previously had a liver transplant.
People with a history of heavy alcohol use, defined as more than 3 standard drinks per day for women or more than 5 standard drinks per day for men.
People who are pregnant at the time of joining the study.
People for whom a liver stiffness scan (called elastography) could not be completed or where that scan data is missing.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Centre Hospitalier Universitaire Saint Pierre

Registry

ClinicalTrials.gov

Start date

1 November 2024

Est. completion

1 October 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Prevalence of NAFLD in the population of IBD patients followed at the University Hospital IBD clinic.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov